vs
EXACT SCIENCES CORP（EXAS）与SouthState Bank Corp（SSB）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是SouthState Bank Corp的1.3倍（$878.4M vs $661.7M），SouthState Bank Corp净利率更高（34.1% vs -9.8%，领先43.9%），过去两年SouthState Bank Corp的营收复合增速更高（37.4% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
SouthState Bank总部位于美国佛罗里达州温特黑文，是银行控股公司SouthState Corporation旗下的银行子公司。截至2025年5月26日，该行已在南卡罗来纳、北卡罗来纳、佐治亚、佛罗里达、阿拉巴马、弗吉尼亚、科罗拉多、得克萨斯八州设有371家营业网点，为当地客户提供各类银行金融服务。
EXAS vs SSB — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$661.7M
净利率更高
SSB
高出43.9%
-9.8%
两年增速更快
SSB
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $661.7M |
| 净利润 | $-86.0M | $225.8M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 15.1% |
| 净利率 | -9.8% | 34.1% |
| 营收同比 | 23.1% | — |
| 净利润同比 | 90.1% | 153.5% |
| 每股收益（稀释后） | $-0.45 | $2.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSSB
| Q1 26 | — | $661.7M | ||
| Q4 25 | $878.4M | $581.1M | ||
| Q3 25 | $850.7M | $599.7M | ||
| Q2 25 | $811.1M | $577.9M | ||
| Q1 25 | $706.8M | $544.5M | ||
| Q4 24 | $713.4M | $369.8M | ||
| Q3 24 | $708.7M | $351.5M | ||
| Q2 24 | $699.3M | $350.3M |
净利润EXASSSB
| Q1 26 | — | $225.8M | ||
| Q4 25 | $-86.0M | $247.7M | ||
| Q3 25 | $-19.6M | $246.6M | ||
| Q2 25 | $-1.2M | $215.2M | ||
| Q1 25 | $-101.2M | $89.1M | ||
| Q4 24 | $-864.6M | $144.2M | ||
| Q3 24 | $-38.2M | $143.2M | ||
| Q2 24 | $-15.8M | $132.4M |
毛利率EXASSSB
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASSSB
| Q1 26 | — | 15.1% | ||
| Q4 25 | -9.4% | 54.3% | ||
| Q3 25 | -3.0% | 53.6% | ||
| Q2 25 | -0.3% | 48.8% | ||
| Q1 25 | -13.6% | 22.3% | ||
| Q4 24 | -122.8% | 50.7% | ||
| Q3 24 | -5.6% | 53.1% | ||
| Q2 24 | -3.8% | 49.3% |
净利率EXASSSB
| Q1 26 | — | 34.1% | ||
| Q4 25 | -9.8% | 42.6% | ||
| Q3 25 | -2.3% | 41.1% | ||
| Q2 25 | -0.1% | 37.2% | ||
| Q1 25 | -14.3% | 16.4% | ||
| Q4 24 | -121.2% | 39.0% | ||
| Q3 24 | -5.4% | 40.7% | ||
| Q2 24 | -2.3% | 37.8% |
每股收益（稀释后）EXASSSB
| Q1 26 | — | $2.28 | ||
| Q4 25 | $-0.45 | $2.47 | ||
| Q3 25 | $-0.10 | $2.42 | ||
| Q2 25 | $-0.01 | $2.11 | ||
| Q1 25 | $-0.54 | $0.87 | ||
| Q4 24 | $-4.69 | $1.88 | ||
| Q3 24 | $-0.21 | $1.86 | ||
| Q2 24 | $-0.09 | $1.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $9.0B |
| 总资产 | $5.9B | $68.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSSB
| Q1 26 | — | $2.9B | ||
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — |
股东权益EXASSSB
| Q1 26 | — | $9.0B | ||
| Q4 25 | $2.4B | $9.1B | ||
| Q3 25 | $2.5B | $9.0B | ||
| Q2 25 | $2.5B | $8.8B | ||
| Q1 25 | $2.4B | $8.6B | ||
| Q4 24 | $2.4B | $5.9B | ||
| Q3 24 | $3.2B | $5.9B | ||
| Q2 24 | $3.2B | $5.7B |
总资产EXASSSB
| Q1 26 | — | $68.0B | ||
| Q4 25 | $5.9B | $67.2B | ||
| Q3 25 | $5.9B | $66.0B | ||
| Q2 25 | $5.8B | $65.9B | ||
| Q1 25 | $5.7B | $65.1B | ||
| Q4 24 | $5.9B | $46.4B | ||
| Q3 24 | $6.7B | $46.1B | ||
| Q2 24 | $6.7B | $45.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASSSB
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | $232.1M | ||
| Q3 25 | $219.9M | $122.4M | ||
| Q2 25 | $89.0M | $72.6M | ||
| Q1 25 | $30.8M | $-126.3M | ||
| Q4 24 | $47.1M | $354.3M | ||
| Q3 24 | $138.7M | $-246.8M | ||
| Q2 24 | $107.1M | $126.8M |
自由现金流EXASSSB
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $215.5M | ||
| Q3 25 | $190.0M | $101.7M | ||
| Q2 25 | $46.7M | $52.5M | ||
| Q1 25 | $-365.0K | $-139.1M | ||
| Q4 24 | $10.7M | $340.9M | ||
| Q3 24 | $112.6M | $-254.2M | ||
| Q2 24 | $71.2M | $117.3M |
自由现金流率EXASSSB
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 37.1% | ||
| Q3 25 | 22.3% | 17.0% | ||
| Q2 25 | 5.8% | 9.1% | ||
| Q1 25 | -0.1% | -25.5% | ||
| Q4 24 | 1.5% | 92.2% | ||
| Q3 24 | 15.9% | -72.3% | ||
| Q2 24 | 10.2% | 33.5% |
资本支出强度EXASSSB
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 2.9% | ||
| Q3 25 | 3.5% | 3.5% | ||
| Q2 25 | 5.2% | 3.5% | ||
| Q1 25 | 4.4% | 2.4% | ||
| Q4 24 | 5.1% | 3.6% | ||
| Q3 24 | 3.7% | 2.1% | ||
| Q2 24 | 5.1% | 2.7% |
现金转化率EXASSSB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | -1.42× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | -1.72× | ||
| Q2 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
